Prostate

Papers
(The H4-Index of Prostate is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Urethral luminal epithelia are castration‐insensitive cells of the proximal prostate56
High intratumoral CD8+ T‐cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy44
Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume40
Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial35
Antitumor efficacy of interferon‐γ‐modified exosomal vaccine in prostate cancer35
The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement34
ATF6α promotes prostate cancer progression by enhancing PLA2G4A‐mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis32
Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF‐1 upregulation of TUBB2B beta‐tubulin isoform31
Targeting CPT1B as a potential therapeutic strategy in castration‐resistant and enzalutamide‐resistant prostate cancer29
Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment26
Escherichia coli, a common constituent of benign prostate hyperplasia‐associated microbiota induces inflammation and DNA damage in prostate epithelial cells26
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer25
Validation of a prostate cancer polygenic risk score24
Association between CD8 and PD‐L1 expression and outcomes after radical prostatectomy for localized prostate cancer23
PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications23
177Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis22
Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration‐resistant prostate cancer patients during abiraterone/enzalutamide treatment22
SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)22
Zonal regulation of collagen‐type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry22
Clinical and genomic features of SPOP‐mutant prostate cancer21
Neuroendocrine differentiation in usual‐type prostatic adenocarcinoma: Molecular characterization and clinical significance21
0.061663866043091